Table 8 Cost change in the scenario: shift from warfarin to DOAC (2018 prices)
Annual costs in EUR (share % from total costs) | Drug retail prices (excl. VAT) | Distributor’s drug prices | ||||
|---|---|---|---|---|---|---|
Baseline | Scenario | Change | Baseline | Scenario | Change | |
Costs of INR monitoring: | 2,974,840 (59.8) | 343,500 (6.7) | −88.5% | 2,881,800 (62.9) | 326,180 (8.2) | −88.7% |
INR measurements and medication (N = 4560) | 2,781,820 (56.0) | 2,688,780 (58.7) | ||||
Time costs of INR monitoring (N = 4560) | 193,020 (3.8) | 193,020 (4.2) | ||||
Patients unable to switch to DOAC (N = 296) | 270,230 (5.3) | 264,190 (6.7) | ||||
Patients not switching to DOAC (< 5 INR M. 2017, N = 553) | 73,270 (1.4) | 61,990 (1.5) | ||||
Travel costs: | 815,090 (16.4) | 97,840 (1.9) | −88.0% | 815,090 (17.8) | 97,840 (2.5) | −88.0% |
Direct travel costs (N = 3961) | 715,990 (14.4) | 715,990 (15.6) | ||||
Travel time costs (N = 3961) | 99,100 (2.0) | 99,100 (2.2) | ||||
Patients continuing warfarin (N = 772) | 97,840 (1.9) | 97,840 (2.5) | ||||
Cost of DOAC therapy: | 1,181,850 (23.8) | 4,661,180 (91.4) | 294.4% | 883,970 (19.3) | 3,531,580 (89.3) | 299.5% |
Patients using DOAC (N = 1239) | 1,181,850 (23.8) | 1,181,850 (23.2) | 883,970 (19.3) | 883,970 (22.3) | ||
Patients switching from warfarin to DOAC (N = 3711) | 3,479,330 (68.2) | 2,647,610 (67.0) | ||||
Total cost of anticoagulation management: | 4,971,780 (100) | 5,102,520 (100) | 2.6% | 4,580,860 (100) | 3,955,600 (100) | −13.6% |